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Abstract
Although the estimate of the incidence of sepsis following transrectal ultrasound-guided prostate biopsy (TRUSPB) is low, ﬂuoroquino-
lone-resistant infections after prostate biopsy are being increasingly noted. This study was aimed at determining the prevalence of faecal
carriage of ﬂuoroquinolone-resistant Escherichia coli strains before TRUSPB and at evaluating potential predisposing risk factors. The inci-
dence of sepsis after prostate biopsy was determined, and our routine practice for antibiotic prophylaxis for TRUSPB was evaluated.
A prospective study was conducted in 342 consecutive patients undergoing prostate biopsy between December 2009 and July 2010.
Before TRUSPB, a rectal swab was cultured. The correlation between the presence of ﬂuoroquinolone-resistant strains and plausible
risk factors was investigated by the use of a questionnaire. Of the 236 patients included, 22.0% (52/236) harboured ciproﬂoxacin-resis-
tant E. coli strains. The use of ﬂuoroquinolones in the 6 months before biopsy was associated with an increased risk of faecal carriage
of ﬂuoroquinolone-resistant E. coli strains (p <0.01). Faecal carriage of ﬂuoroquinolone-resistant E. coli strains was an important risk fac-
tor for infectious complications after TRUSPB (p <0.01). In conclusion, a signiﬁcant number of patients have faecal carriage of ﬂuoro-
quinolone-resistant E. coli strains (22.0%) before TRUSPB. The use of ﬂuoroquinolones in the previous 6 months before biopsy is a risk
factor for faecal carriage of ﬂuoroquinolone-resistant E. coli strains and for infectious complications after TRUSPB. Hence, the universal
administration of ﬂuoroquinolones should be reconsidered.
Keywords: Antibiotic prophylaxis, Escherichia coli, ﬂuoroquinolone resistance, transrectal ultrasound-guided prostate biopsy, urosepsis
Original Submission: 7 June 2011; Revised Submission: 15 July 2011; Accepted: 15 July 2011
Editor: F. Allerberger
Article published online: 22 July 2011
Clin Microbiol Infect 2012; 18: 575–581
10.1111/j.1469-0691.2011.03638.x
Corresponding author: D. Steensels and J. Verhaegen,
Department of Laboratory Medicine—;Microbiology, Universitaire
Ziekenhuizen Leuven Gasthuisberg, Herestraat 49, B-3000 Leuven,
Belgium.
E-mails: deborah.steensels@uzleuven.be;
jan.verhaegen@uzleuven.be
Introduction
Transrectal ultrasound-guided prostate biopsy (TRUSPB) is a
commonly performed procedure for the diagnosis of pros-
tate cancer. The risks and complications of TRUSPB are well
known. Clinically signiﬁcant infectious complications include
urinary tract infection (UTI), acute bacterial prostatitis,
orchiepididymitis, and sepsis [1].
Several studies have demonstrated the value of antibiotic
prophylaxis before TRUSPB. In a randomized, double-blind,
controlled study reported in 1998, Kapoor et al. [2] noted
that the use of ciproﬂoxacin before transrectal prostate
biopsy resulted in a lower incidence of UTIs and a lower
number of patients who needed to be hospitalized because
of febrile UTIs than in the placebo group. Aron et al.
reported that infective complication rates decreased three-
fold when ﬂuoroquinolones were used as compared with
placebo (8% vs. 25%) [3]. It is noteworthy that all UTIs
yielding positive cultures after prostate biopsy were suscepti-
ble to ﬂuoroquinolones. In 1998, Sieber et al. [4] reported
only two cases of UTI that were resistant to ﬂuoroquinol-
ones in a series of 4439 TRUSBPs with ﬂuoroquinolone
prophylaxis.
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However, are these values still valid in our dynamic environ-
ment of antimicrobial resistance? Recent studies have shown
that infections with ﬂuoroquinolone-resistant Escherichia coli
after prostate biopsy are increasingly being noted [1,5–8].
At our centre, c. 800 TRUSPBs are performed each year.
Patients receive 500 mg of oral levoﬂoxacin or ciproﬂoxacin
12–1 h before the procedure, and 500 mg daily for 3 days after
the procedure. From 2003 to 2009, the overall incidence of
documented sepsis with E. coli after TRUSPB was 0.95% (54/
5663). In addition, one patient developed septicaemia caused by
Bacteroides fragilis, another developed septicaemia caused by a
ﬂuoroquinolone-sensitive Klebsiella oxytoca strain. Neverthe-
less, this estimate of incidence was retrospective, and was based
on the assumption that all patients with sepsis after prostate
biopsy reported back to our hospital and that blood cultures
were performed. Therefore, the number of cases reported was
probably an underestimate, because some patients may have
reported to other hospitals and some patients may have been
treated empirically. Although the estimate of incidence of sepsis
following TRUSPB is low, ﬂuoroquinolone-resistant infections
after prostate biopsy are increasingly being noted at our centre
(Fig. 1). It is noteworthy that the biopsy protocol remained
exactly the same during this 6-year period.
In parallel, we investigated the evolution of antibiotic
resistance among E. coli strains from the urine of all men
‡45 years old over the same period (Fig. 2). A signiﬁcant
increase in ciproﬂoxacin resistance between 2003–2005 and
2006–2009 (p <0.01) was observed. This increase in ﬂuor-
oquinolone resistance correlated with the increasing inci-
dence of post-TRUSPB sepsis in the same period (Fig. 1).
Because of the increasing number of patients who are
being admitted for post-TRUSPB sepsis at our centre, and the
increasing ﬂuoroquinolone resistance in E. coli, a prospective
study was conducted. Our ﬁrst aim was to determine the
prevalence of faecal carriage of ﬂuoroquinolone-resistant
E. coli strains before TRUSPB and to evaluate potential predis-
posing risk factors. A second aim was to determine the inci-
dence of sepsis after TRUSPB, and to evaluate our routine
practice for antibiotic prophylaxis for TRUSPB.
Patients and Methods
Prospective study
The prospective study started on 1 December 2009, and all
patients undergoing TRUSPB at our centre were included. A
questionnaire was ﬁlled out by the urologist for each patient
on the number of previous prostate biopsies, on the pres-
ence of symptoms of chronic prostatitis (clinical diagnosis,
not culture-proven), and on the use of ﬂuoroquinolones in
the 6-month period before TRUSPB.
Rectal swabs were obtained immediately prior to the
prostate biopsy. These swabs were transferred within 2 h to
the laboratory in AMIES transport medium (Nuova APT-
ACA, Canelli, Italy) and plated on MacConkey agar and on
MacConkey agar with ciproﬂoxacin 1 mg/L. After incubation
at 37C for 24 h, ciproﬂoxacin-resistant strains were identi-
ﬁed with the Vitek 2 system (Biomerieux, Lyon, France), and
the MIC for ciproﬂoxacin was determined with an Etest (AB
biodisk; Biomerieux).
Patients received 500 mg of oral levoﬂoxacin or ciproﬂox-
acin 12–1 h before the procedure and 500 mg daily for
3 days after the procedure. Oral anticoagulant agents were
stopped 7–10 days before biopsy. Enemas were not given
before biopsy.
Biopsy technique
The biopsies were performed by two radiologists, using the
same protocol. Transrectal ultrasound was performed with a
multiplanar multifrequency probe (7.5 MHz) attached to the
ultrasound scanner. Prostate biopsy specimens were taken
with an 18 gauge · 20-cm biopsy cut with an automated
spring-loaded gun. They were obtained at the apex, middle
and base of the left and right prostate lobes in the parasagittal
plane. Approximately 10–12 cores were obtained, depending
on the prostate volume. From each topographic zone, a sepa-
rate core was sent for histopathological investigation.
Statistical analysis
Results were compared by the use of Fisher’s exact test. All
tests were two-tailed and were considered signiﬁcant when
p <0.05.
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FIG. 1. Incidence of sepsis after transrectal ultrasound-guided pros-
tate biopsy (TRUSPB) (bars, left axis) and ﬂuoroquinolone resistance
in Escherichia coli from urine cultures of all men ‡45 years old (line,
right axis) in the periods 2003 to November 2009 (retrospectively)
and December 2009 to July 2010 (prospectively).
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Study approval
The ethics committees of the hospital approved the study.
Results
Culture results
Of the 342 patients who underwent TRUSPB during the
study period, 53 had a negative rectal swab culture. These
patients were excluded from further analysis, because it was
unclear whether this was caused by a problem with speci-
men collection or the antibiotic prophylaxis. Patients who
did not receive antibiotic prophylaxis (N = 31) or received
prophylaxis with an antibiotic other than a ﬂuoroquinolone
(N = 22) (e.g. co-trimoxazole) were also excluded. In gen-
eral, patients referred for biopsy by the general practitioner
did not receive prophylaxis, and those who received an anti-
biotic other than a ﬂuoroquinolone were most often treated
for a pre-existing infection.
Of the remaining 236 rectal cultures, 178 showed growth
on MacConkey agar but not on MacConkey agar with cipro-
ﬂoxacin 1 mg/L, indicating that these patients harboured
ciproﬂoxacin-sensitive strains. There was growth on both
MacConkey agars for 58 rectal cultures. In 52 cultures, the
microorganism was identiﬁed as E. coli. The MIC of cipro-
ﬂoxacin was ‡32 mg/L in 34 of 52 (65.4%) E. coli strains. For
the remaining 18 E. coli strains, the MICs were 4 (N = 1), 8
(N = 9), or 16 (N = 8).
For the other six cultures with growth on both MacCon-
key agars, the microorganisms were identiﬁed as Pseudomo-
nas aeruginosa (N = 2), Comamonas kerstersii (N = 2), Proteus
mirabilis (N = 1), and Candida albicans (N = 1). Thus, 22.0%
(52/236) of the patients harboured faecal ciproﬂoxacin-resis-
tant E. coli strains.
Risk factors for rectal carriage of ciproﬂoxacin-resistant
E. coli
Two patient groups, namely those who harboured faecal
ciproﬂoxacin-sensitive strains and those with ciproﬂoxacin-
resistant E. coli strains, were compared. There was no statis-
tically signiﬁcant difference in age or prostate-speciﬁc antigen
level between the groups (Table 1).
Only 15 of 178 (8.4%) of patients colonized with ﬂuoroqu-
inolone-susceptible E. coli strains used ﬂuoroquinolones dur-
ing the 6 months before TRUSPB, in contrast to 20 of 52
(38.5%) of patients colonized with ﬂuoroquinolone-resistant
E. coli strains (p <0.01). This implies that the use of ﬂuoro-
quinolones <6 months before biopsy is a risk factor for fae-
cal carriage of ﬂuoroquinolone-resistant strains. We also
found a correlation with the presence of chronic prostatitis
(p <0.01). Of the patients without chronic prostatitis who
used ﬂuoroquinolones <6 months before biopsy, 50% (13/
26) harboured a faecal ciproﬂoxacin-resistant E. coli strain, as
compared with 77.8% (2/9) of the patients with chronic
prostatitis who used ﬂuoroquinolones <6 months before
biopsy (p 0.24). Patients who underwent a repeat biopsy
were not at higher risk for faecal carriage of ﬂuoroquino-
lone-resistant strains than patients who underwent their ﬁrst
biopsy (p 0.64).
Patients with infectious complications
During this prospective study, seven of 236 patients (3.0%)
reported back to our hospital with infectious complications,
all caused by ciproﬂoxacin-resistant E. coli (7/58), as
compared with no patients who harboured faecal ciproﬂoxa-
cin-sensitive strains (0/178) (p <0.01). Faecal carriage of
ﬂuoroquinolone-resistant E. coli strains is therefore an impor-
tant risk factor for infectious complications after TRUSPB.
Six (2.5%) patients presented with sepsis, and another
60
70
40
50
Ampicilin
20
30
A /moxicillin clavulanate
Trimethoprim/sulfamethoxazole
Ciprofloxacin
Cefuroxime
Cefotaxime
10E.
 c
ol
i n
on
-s
us
ce
pƟ
bl
e 
is
ol
at
es
 (%
)
Amikacin
0
2003 2004 2005 2006 2007 2008 2009
Year
FIG. 2. Antibiotic resistance in Escherichia coli from urine cultures of all men ‡45 years old in the period 2003–2009.
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patient was hospitalized with an epididymitis 3 weeks after
biopsy.
The high number of patients who reported back to our
hospital with sepsis caused by ciproﬂoxacin-resistant E. coli
indicates that the true incidence of sepsis after prostate
biopsy at our institute is higher than determined retrospec-
tively in 2003–2009 (0.95%).
Among the six cases of sepsis with a ciproﬂoxacin-resis-
tant E. coli strain, ﬁve patients had a history of previous use
of ﬂuoroquinolones <6 months before the actual biopsy.
Two of them had also a history of chronic prostatitis. Five of
six underwent a ﬁrst set of TRUSPBs. The patients’ charac-
teristics and the antimicrobial susceptibilities of the blood
isolates are shown in Table 2. All six isolates were resistant
to levoﬂoxacin and amoxycillin, and ﬁve of them were also
resistant to co-trimoxazole. Three isolates were not suscep-
tible to aminoglycosides, and one isolate produced an
extended-spectrum b-lactamase.
The mean interval between TRUSPB and presentation to
the emergency room with symptoms of sepsis was 1.3 days
(range 1–2 days). Three patients were treated empirically
with intravenous cefuroxime, two patients were treated with
intravenous amikacin–cefotaxime, and one patient was trea-
ted with intravenous temocillin. There were no cases of sep-
tic shock and no deaths. Antibiotic regimens were adjusted
according to the antimicrobial susceptibility testing results of
blood cultures: oral cefuroxime (N = 1), oral amoxycillin–
clavulanate (N = 2), oral trimethoprim–sulphamethoxazole
(N = 1), intravenous meropenem (N = 1), and intravenous
temocillin (N = 1). All patients were prescribed antibiotics
for a duration of 3–4 weeks.
Discussion
The ﬁrst study of the prevalence of antimicrobial resistance
in coliforms in the rectal ﬂora of patients undergoing TRUS-
PB was published in 2010 by Batura et al. [9]. They found a
10.6% prevalence of ciproﬂoxacin resistance in 500 British
men undergoing TRUSPB. In addition, there was a strong
correlation between the antimicrobial sensitivity of the coli-
forms from the rectal swabs and that of those cultured from
urine or blood. Moreover, a recent study by Liss et al. [10]
found a prevalence of 22% of patients harbouring ﬂuoroqui-
nolone-resistant E. coli. Our prospective study has also
revealed a signiﬁcant number of patients with faecal carriage
of ﬂuoroquinolone-resistant E. coli strains (22.0%) before
TRUSPB, which poses a risk for infectious complications.
The use of ﬂuoroquinolones in the 6 months before biopsy
and the presence of chronic prostatitis were associated with
faecal carriage of ﬂuoroquinolone-resistant E. coli strains,
whereas the presence of chronic prostatitis was not an inde-
pendent risk factor. There are several limitations to our
study. First, we did not make a distinction between cipro-
ﬂoxacin and levoﬂoxacin or other ﬂuoroquinolones.
Although there are pharmacokinetic and in vitro differences
between individual ﬂuoroquinolones, we did not consider
these differences to be important in this setting. Ciproﬂoxa-
cin has better in vitro activity than levoﬂoxacin, but has lower
intestinal absorption than levoﬂoxacin (60–70% vs. >95%)
[11,12]. Second, the rectal swab was taken after the adminis-
tration of the ﬁrst dose of antibiotic. This implies that the
administration could have inﬂuenced the microbiological
result. Ideally, the swab should be taken before the adminis-
tration of antibiotic (e.g. at the time of biopsy scheduling),
but as the mean time between this administration and biopsy
was 2 h, we estimate that this time is too short to substan-
tially inﬂuence the bacterial composition of the rectal ﬂora.
Finally, the determination of incidence assumed that all
patients with sepsis after prostate biopsy reported back to
our hospital. At the time of discharge, patients were asked
to report back to our hospital in case of fever. As some
patients may have reported to other hospitals, the number
of cases reported was possibly an underestimate.
Several studies have already investigated the presence of
ﬂuoroquinolone-resistant strains of E. coli in the stools of
TABLE 1. Analysis of risk factors for carriage of ﬂuoroquinolone-resistant microorganisms
Ciproﬂoxacin-sensitive (N = 178)
Ciproﬂoxacin-resistant (N = 58)
Escherichia coli (N = 52) Othera (N = 6)
Mean age (years) 65.8 67.2 68.3
Median PSA before biopsy (lg/L) 6.7 6.7 9.9
Previous biopsy, no. (%) 69 (38.8) 22 (42.3) 3 (50.0)
Use of ﬂuoroquinolones <6 months before biopsy 15 (8.4) 20 (38.5) 1 (16.7)
Chronic prostatitis 5 (2.8) 11 (21.1) 1 (16.7)
Hospitalization after biopsy 0 (0) 7 (13.5) 0 (0)
PSA, prostate-speciﬁc antigen.
aPseudomonas aeruginosa (N = 2), Comamonas kerstersii (N = 2), Proteus mirabilis (N = 1), and Candida albicans (N = 1).
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patients receiving ﬂuoroquinolone prophylaxis. Shigehara
et al. [13] suggested that previous use of levoﬂoxacin might
cause bacterial selection of resistant E. coli in the rectum.
Yagci et al. [14] found that ﬂuoroquinolone use 6 months
prior to the biopsy was a risk factor for ﬂuoroquinolone-
resistant E. coli carriage, and that the prevalence of ﬂuoroqui-
nolone-resistant E. coli strains in faecal ﬂora increased stea-
dily with the duration of ﬂuoroquinolone therapy. Taken
together, these studies and our results highlight the impor-
tance of reviewing a patient’s history before prescribing a
prophylaxis regimen.
The value of antibiotic prophylaxis has been demonstrated
by several studies, but there are wide variations in antibiotic
regimens and administration [2,4,15]. The American Uro-
logical Association recommends a ﬂuoroquinolone or
second-generation or third-generation cephalosporin as the
antimicrobial agent of choice, and an aminoglycoside plus
metronidazole or clindamycin as the alternative. No speciﬁc
recommendations are given concerning the timing of admin-
istration. The recommended duration is £24 h, with
extended coverage for £3–4 days in patients with comorbid
conditions [16].
TABLE 2. Patient characteristics and antimicrobial susceptibility of the blood isolates
Patient no. 1 2 3 4 5 6
Age (years) 70 70 61 59 71 54
Biopsy indication Elevated PSA Elevated PSA Elevated PSA Elevated PSA Elevated PSA Chronic
prostatitis
Biopsy date 22/12/2009 28/12/2009 30/12/2009 15/02/2010 16/04/2010 30/04/2010
Date of hospitalization 23/12/2009 29/12/2009 01/01/2010 16/02/2010 18/04/2010 01/05/2010
History of biopsy Third First First Unknown First First
PSA (lg/L) 14.33 13.0 4.66 4.90 7.80 1.22
Pathology No malignancy Invasive
adenocarcinoma
No malignancy Invasive
adenocarcinoma
Invasive
adenocarcinoma
Invasive
adenocarcinoma
Medical history Chronic prostatitis and
orchitis
Post-TRUSPB sepsis (2007)
Sleep apnoea
Drug-eluting
stent 05/2009
Hip prosthesis
Sleep apnoea
Pneumonia
(2007)
Alcohol abuse
Hip
prosthesis
Amygdalectomy
Antimicrobial history Several courses of
ﬂuoroquinolone
in the past
30 days of
ﬂuoroquinolone
before biopsy
6 weeks of
ﬂuoroquinolone starting
from 09/09/2009
Unknown 6 weeks of
ﬂuoroquinolone
starting
from 26/02/2010
5 weeks of
norﬂoxacin
starting
from 26/03/2010
Antimicrobial susceptibility of blood isolatesa
Levoﬂoxacin R R R R R R
Amoxycillin R R R R R R
Amoxycillin–clavulanate I I S I R S
Piperacillin–tazobactam S S S S R S
Meropenem S S S S S S
Cefazolin S S S R S S
Cefuroxime S S S R I I
Cefotaxime S S S R S S
Ceftazidime S S S R S S
Amikacin S S S I S S
Gentamicin S S R S R S
Tobramycin S S R I R S
Temocillin S S S S S S
Trimethoprim–sulphamethoxazole R R R R R S
ESBL ) ) ) + ) )
ESBL, extended-spectrum b-lactamase; I, intermediate; PSA, prostate-speciﬁc antigen; R, resistant; S, sensitive; TRUSPB, transrectal ultrasound-guided prostate biopsy.
aCLSI breakpoints.
TABLE 3. Proposal for protocol for antimicrobial prophylaxis at UZ Leuven
Antimicrobial of choice Duration of therapy
Patients without risk factors FQ 500 mg 2 h before biopsy Single dose
Patients with risk factors
FQ use in the previous 6 months
Prior infectious complications of TRUSPB
Recurrent bacterial prostatitis or UTIs
Rectal swab: FQ
FQ:S ﬁ FQ 500 mg 2 h before biopsy
FQ: R ﬁ ceftriaxone 1 g IM 1–3 h before biopsy (or IV 30 min before biopsy)
ESBL ﬁ meropenem 1 g IV 30 min before biopsy
Single dose
Single dose
Single dose
ESBL, extended spectrum b-lactamase; FQ, ﬂuoroquinolone; IM, intramuscular; IV, intravenous; TRUSPB, transrectal ultrasound-guided prostate biopsy; UTI, urinary tract
infection.
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In the wake of the increased ﬂuoroquinolone resistance in
E. coli strains, several interventional studies have compared
different antibiotic prophylactic regimens for TRUSPB
[17–21]. Overall, the authors replace an oral ﬂuoroquinolone
with another antibiotic (e.g. piperacillin–tazobactam [17] or
ceftriaxone [18]) or they add another antibiotic to an oral
ﬂuoroquinolone (e.g. cefoxitin [19], gentamicin [20], or
amikacin [21]).
In order to implement an alternative preventive protocol
for patients with a high risk of faecal carriage of
ﬂuoroquinolone-resistant strains before biopsy and/or
infectious complications, consideration should be given not
only to a regimen’s efﬁcacy, but also its cost and clinical
applicability. We now recommend ceftriaxone as an alterna-
tive option (Table 3). Indeed, in 2009, 90.2% of E. coli
strains isolated from urine samples were susceptible to
third-generation cephalosporins (Fig. 2). Surgical prophylaxis
is traditionally administered intravenously within 1 h before
surgery. We propose, however, intramuscular administration
1–3 h before biopsy, because this is easier and the bioavail-
ability and serum levels for a 1-g intramuscular dose and a
1-g intravenous dose of ceftriaxone are comparable [22,23].
Ceftriaxone does not signiﬁcantly increase the risk of
an allergic reaction among patients with penicillin allergy
[24].
Alternatively, a rectal swab could be obtained before
TRUSPB in patients with a high risk of faecal carriage of ﬂu-
oroquinolone-resistant E. coli strains. A possible drawback
of this strategy is the practical applicability. The swab has
to be taken at least 24 h and preferably 48 h before biopsy.
This means that culture must be performed by the general
practitioner or that patients who attended the outpatient
clinic will have to come back to the hospital, after the
results of the culture are known. On the other hand, this
strategy would allow us to reserve broad-spectrum antibi-
otic agents such as ceftriaxone for those high-risk patients
harbouring ﬂuoroquinolone-resistant E. coli strains in the
rectum. Another advantage is the detection of extended-
spectrum b-lactamase-producing E. coli strains. Thus, rectal
swab screening cultures before TRUSPB may provide useful
evidence for the selection of appropriate antimicrobials for
prophylaxis and the treatment of TRUSPB-associated
infections.
On the basis of the results of this prospective study, a
new protocol for antimicrobial prophylaxis before TRUSPB
was implemented (Table 3). The validation of this protocol is
ongoing. In conclusion, our results suggest a challengingly
high prevalence of faecal carriage of ﬂuoroquinolone-resistant
E. coli strains before TRUSPB, and a relatively high incidence
of infectious complications (3.0%) after TRUSPB.
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